De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients

Motoko Yamaguchi, Masao Seto, Masataka Okamoto, Ryo Ichinohasama, Naoya Nakamura, Tadashi Yoshino, Junji Suzumiya, Takuhei Murase, Ikuo Miura, Takashi Akasaka, Jun Ichi Tamaru, Ritsuro Suzuki, Yoshitoyo Kagami, Masami Hirano, Yasuo Morishima, Ryuzo Ueda, Hiroshi Shiku, Shigeo Nakamura

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

De novo CD5 + diffuse large B-cell lymphoma (CD5 + DLBCL) is known to have phenotypically and genotypically different characteristics than CD5 - DLBCL and mantle cell lymphoma (MCL). To further characterize CD5 + DLBCL, 109 patients with CD5 + DLBCL were reviewed, and the results were compared with those of 384 CD5 - DLBCL and 128 cyclin D1 + MCL patients. Patients with CD5 + DLBCL showed a higher age distribution (median, 66 years; P = .0083) and a female predominance (male-female ratio, 49:60, P = .011) compared with those with CD5 - DLBCL. CD5 + DLBCL was more closely associated with many aggressive clinical features or parameters than CD5 - DLBCL: 69% older than 60 years (P = .039), 34% with performance status greater than 1 (P = .0016), 69% with serum lactate dehydrogenase level higher than normal (P <.0001), 62% with stage III/IV disease at diagnosis (P = .0023), 35% with more than one extranodal site (P = .023), and 40% with B symptoms (P = .0031). The overall International Prognostic Index score was thus significantly higher for the patients with CD5 + DLBCL than for those with CD5 - DLBCL (P = .00005). The most frequent site of extranodal involvement was bone marrow (28%), a higher frequency than that for CD5 - DLBCL (P <.0001) but lower than that for cyclin D1 + MCL (P = .0015). Histopathologically, CD5 + DLBCL showed centroblastic morphology except for 3 patients with immunoblastic disease, and interfollicular growth pattern (7%) and intravascular or intrasinusoidal infiltration (19%) were observed. Immunophenotypically, CD5 + DLBCL was characterized by a CD5 +CD10 -CD19 + CD20 +CD21 -CD23 - cyclin D1 - phenotype and a predominance of surface IgMκ. Of particular interest is that CD5 + DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5 - DLBCL (P = .0026). These findings suggest that CD5 + DLBCL may constitute a unique subgroup of DLBCL.

Original languageEnglish
Pages (from-to)815-821
Number of pages7
JournalBlood
Volume99
Issue number3
DOIs
Publication statusPublished - Feb 1 2002

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cyclin D1
Cells
Mantle-Cell Lymphoma
L-Lactate Dehydrogenase
Infiltration
Immunoglobulin M
Bone
Age Distribution
Bone Marrow
Phenotype
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Yamaguchi, M., Seto, M., Okamoto, M., Ichinohasama, R., Nakamura, N., Yoshino, T., ... Nakamura, S. (2002). De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood, 99(3), 815-821. https://doi.org/10.1182/blood.V99.3.815

De novo CD5 + diffuse large B-cell lymphoma : A clinicopathologic study of 109 patients. / Yamaguchi, Motoko; Seto, Masao; Okamoto, Masataka; Ichinohasama, Ryo; Nakamura, Naoya; Yoshino, Tadashi; Suzumiya, Junji; Murase, Takuhei; Miura, Ikuo; Akasaka, Takashi; Tamaru, Jun Ichi; Suzuki, Ritsuro; Kagami, Yoshitoyo; Hirano, Masami; Morishima, Yasuo; Ueda, Ryuzo; Shiku, Hiroshi; Nakamura, Shigeo.

In: Blood, Vol. 99, No. 3, 01.02.2002, p. 815-821.

Research output: Contribution to journalArticle

Yamaguchi, M, Seto, M, Okamoto, M, Ichinohasama, R, Nakamura, N, Yoshino, T, Suzumiya, J, Murase, T, Miura, I, Akasaka, T, Tamaru, JI, Suzuki, R, Kagami, Y, Hirano, M, Morishima, Y, Ueda, R, Shiku, H & Nakamura, S 2002, 'De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients', Blood, vol. 99, no. 3, pp. 815-821. https://doi.org/10.1182/blood.V99.3.815
Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T et al. De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood. 2002 Feb 1;99(3):815-821. https://doi.org/10.1182/blood.V99.3.815
Yamaguchi, Motoko ; Seto, Masao ; Okamoto, Masataka ; Ichinohasama, Ryo ; Nakamura, Naoya ; Yoshino, Tadashi ; Suzumiya, Junji ; Murase, Takuhei ; Miura, Ikuo ; Akasaka, Takashi ; Tamaru, Jun Ichi ; Suzuki, Ritsuro ; Kagami, Yoshitoyo ; Hirano, Masami ; Morishima, Yasuo ; Ueda, Ryuzo ; Shiku, Hiroshi ; Nakamura, Shigeo. / De novo CD5 + diffuse large B-cell lymphoma : A clinicopathologic study of 109 patients. In: Blood. 2002 ; Vol. 99, No. 3. pp. 815-821.
@article{4b77732683404964b6df28d48727101d,
title = "De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients",
abstract = "De novo CD5 + diffuse large B-cell lymphoma (CD5 + DLBCL) is known to have phenotypically and genotypically different characteristics than CD5 - DLBCL and mantle cell lymphoma (MCL). To further characterize CD5 + DLBCL, 109 patients with CD5 + DLBCL were reviewed, and the results were compared with those of 384 CD5 - DLBCL and 128 cyclin D1 + MCL patients. Patients with CD5 + DLBCL showed a higher age distribution (median, 66 years; P = .0083) and a female predominance (male-female ratio, 49:60, P = .011) compared with those with CD5 - DLBCL. CD5 + DLBCL was more closely associated with many aggressive clinical features or parameters than CD5 - DLBCL: 69{\%} older than 60 years (P = .039), 34{\%} with performance status greater than 1 (P = .0016), 69{\%} with serum lactate dehydrogenase level higher than normal (P <.0001), 62{\%} with stage III/IV disease at diagnosis (P = .0023), 35{\%} with more than one extranodal site (P = .023), and 40{\%} with B symptoms (P = .0031). The overall International Prognostic Index score was thus significantly higher for the patients with CD5 + DLBCL than for those with CD5 - DLBCL (P = .00005). The most frequent site of extranodal involvement was bone marrow (28{\%}), a higher frequency than that for CD5 - DLBCL (P <.0001) but lower than that for cyclin D1 + MCL (P = .0015). Histopathologically, CD5 + DLBCL showed centroblastic morphology except for 3 patients with immunoblastic disease, and interfollicular growth pattern (7{\%}) and intravascular or intrasinusoidal infiltration (19{\%}) were observed. Immunophenotypically, CD5 + DLBCL was characterized by a CD5 +CD10 -CD19 + CD20 +CD21 -CD23 - cyclin D1 - phenotype and a predominance of surface IgMκ. Of particular interest is that CD5 + DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5 - DLBCL (P = .0026). These findings suggest that CD5 + DLBCL may constitute a unique subgroup of DLBCL.",
author = "Motoko Yamaguchi and Masao Seto and Masataka Okamoto and Ryo Ichinohasama and Naoya Nakamura and Tadashi Yoshino and Junji Suzumiya and Takuhei Murase and Ikuo Miura and Takashi Akasaka and Tamaru, {Jun Ichi} and Ritsuro Suzuki and Yoshitoyo Kagami and Masami Hirano and Yasuo Morishima and Ryuzo Ueda and Hiroshi Shiku and Shigeo Nakamura",
year = "2002",
month = "2",
day = "1",
doi = "10.1182/blood.V99.3.815",
language = "English",
volume = "99",
pages = "815--821",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - De novo CD5 + diffuse large B-cell lymphoma

T2 - A clinicopathologic study of 109 patients

AU - Yamaguchi, Motoko

AU - Seto, Masao

AU - Okamoto, Masataka

AU - Ichinohasama, Ryo

AU - Nakamura, Naoya

AU - Yoshino, Tadashi

AU - Suzumiya, Junji

AU - Murase, Takuhei

AU - Miura, Ikuo

AU - Akasaka, Takashi

AU - Tamaru, Jun Ichi

AU - Suzuki, Ritsuro

AU - Kagami, Yoshitoyo

AU - Hirano, Masami

AU - Morishima, Yasuo

AU - Ueda, Ryuzo

AU - Shiku, Hiroshi

AU - Nakamura, Shigeo

PY - 2002/2/1

Y1 - 2002/2/1

N2 - De novo CD5 + diffuse large B-cell lymphoma (CD5 + DLBCL) is known to have phenotypically and genotypically different characteristics than CD5 - DLBCL and mantle cell lymphoma (MCL). To further characterize CD5 + DLBCL, 109 patients with CD5 + DLBCL were reviewed, and the results were compared with those of 384 CD5 - DLBCL and 128 cyclin D1 + MCL patients. Patients with CD5 + DLBCL showed a higher age distribution (median, 66 years; P = .0083) and a female predominance (male-female ratio, 49:60, P = .011) compared with those with CD5 - DLBCL. CD5 + DLBCL was more closely associated with many aggressive clinical features or parameters than CD5 - DLBCL: 69% older than 60 years (P = .039), 34% with performance status greater than 1 (P = .0016), 69% with serum lactate dehydrogenase level higher than normal (P <.0001), 62% with stage III/IV disease at diagnosis (P = .0023), 35% with more than one extranodal site (P = .023), and 40% with B symptoms (P = .0031). The overall International Prognostic Index score was thus significantly higher for the patients with CD5 + DLBCL than for those with CD5 - DLBCL (P = .00005). The most frequent site of extranodal involvement was bone marrow (28%), a higher frequency than that for CD5 - DLBCL (P <.0001) but lower than that for cyclin D1 + MCL (P = .0015). Histopathologically, CD5 + DLBCL showed centroblastic morphology except for 3 patients with immunoblastic disease, and interfollicular growth pattern (7%) and intravascular or intrasinusoidal infiltration (19%) were observed. Immunophenotypically, CD5 + DLBCL was characterized by a CD5 +CD10 -CD19 + CD20 +CD21 -CD23 - cyclin D1 - phenotype and a predominance of surface IgMκ. Of particular interest is that CD5 + DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5 - DLBCL (P = .0026). These findings suggest that CD5 + DLBCL may constitute a unique subgroup of DLBCL.

AB - De novo CD5 + diffuse large B-cell lymphoma (CD5 + DLBCL) is known to have phenotypically and genotypically different characteristics than CD5 - DLBCL and mantle cell lymphoma (MCL). To further characterize CD5 + DLBCL, 109 patients with CD5 + DLBCL were reviewed, and the results were compared with those of 384 CD5 - DLBCL and 128 cyclin D1 + MCL patients. Patients with CD5 + DLBCL showed a higher age distribution (median, 66 years; P = .0083) and a female predominance (male-female ratio, 49:60, P = .011) compared with those with CD5 - DLBCL. CD5 + DLBCL was more closely associated with many aggressive clinical features or parameters than CD5 - DLBCL: 69% older than 60 years (P = .039), 34% with performance status greater than 1 (P = .0016), 69% with serum lactate dehydrogenase level higher than normal (P <.0001), 62% with stage III/IV disease at diagnosis (P = .0023), 35% with more than one extranodal site (P = .023), and 40% with B symptoms (P = .0031). The overall International Prognostic Index score was thus significantly higher for the patients with CD5 + DLBCL than for those with CD5 - DLBCL (P = .00005). The most frequent site of extranodal involvement was bone marrow (28%), a higher frequency than that for CD5 - DLBCL (P <.0001) but lower than that for cyclin D1 + MCL (P = .0015). Histopathologically, CD5 + DLBCL showed centroblastic morphology except for 3 patients with immunoblastic disease, and interfollicular growth pattern (7%) and intravascular or intrasinusoidal infiltration (19%) were observed. Immunophenotypically, CD5 + DLBCL was characterized by a CD5 +CD10 -CD19 + CD20 +CD21 -CD23 - cyclin D1 - phenotype and a predominance of surface IgMκ. Of particular interest is that CD5 + DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5 - DLBCL (P = .0026). These findings suggest that CD5 + DLBCL may constitute a unique subgroup of DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=0036464704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036464704&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.3.815

DO - 10.1182/blood.V99.3.815

M3 - Article

C2 - 11806981

AN - SCOPUS:0036464704

VL - 99

SP - 815

EP - 821

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -